论文部分内容阅读
目的:分析金砖国家被忽视疾病研发筹资情况。方法:对世界银行和经合组织数据库、金砖国家卫生部和科技部官方报告中涉及研发或卫生研发的相关数据,以及G-FINDER调查收集的被忽视疾病研发投入的数据进行分析。结果:2007—2014年巴西、俄罗斯、印度、中国和南非的公共部门在被忽视疾病领域分别投入了1.72亿、0.38亿、2.86亿、0.28亿和0.54亿美元,2011年5国被忽视疾病研发领域的投入占卫生研发投入的比例分别为1.92%、1.27%(2007年)、0.91%、0.16%和1.38%。巴西和印度关注的疾病种类较广泛,南非、中国和俄罗斯都主要关注HIV/AIDS。结论:虽然被忽视疾病主要影响发展中国家,但目前发达国家是研发投入的主体。尽管与发达国家无法相比肩,金砖国家的投入比其他发展中国家要高;而且其研发投入主要针对本国的疾病负担。尽管如此,与本国的疾病负担相比金砖国家在被忽视疾病领域的研发投入仍旧不足。
Objective: To analyze the financing of neglected diseases in BRICS countries. Methods: Analyzes data related to R & D or health research and development in the official reports of the World Bank and OECD databases, the BRICS Ministry of Health and Ministry of Science and Technology, as well as input from R & D on neglected diseases collected through the G-FINDER survey. Results: In 2007-2014, the public sector in Brazil, Russia, India, China and South Africa invested 172 million, 38 million, 286 million, 028 million and 544 million respectively in neglected diseases. In 2011, the research and development of neglected diseases in 5 countries Investment in health research and development in the area accounted for 1.92%, 1.27% (2007), 0.91%, 0.16% and 1.38%, respectively. Brazil and India are more concerned about the types of diseases, with South Africa, China and Russia focusing mainly on HIV / AIDS. Conclusion: Although neglected diseases mainly affect developing countries, currently developed countries are the main body of R & D investment. Although not comparable with developed countries, BRICS investment is higher than that of other developing countries; and their R & D investment mainly targets the disease burden in their own countries. However, R & D investment by BRICS in neglected diseases is still not enough compared with the national burden of disease.